HLB Group has appointed Yang Eun-young, a seasoned expert in pharmaceutical and biotech business development, as president of its bio business development division. This strategic move precedes anticipated FDA approvals for two cancer drugs, rivoceranib-camrelizumab combination therapy and lirafugratinib. Yang’s background includes leadership roles at CHA Biotech Group and Samsung Biologics, where she expanded business development efforts. Her expertise is expected to strengthen HLB’s commercialization strategies, emphasizing global partnerships and market access as the company aims to translate R&D successes into business outcomes.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://en.sedaily.com/finance/2026/05/04/hlb-hires-ex-cha-biotech-executive-yang-eun-young-ahead-of
